Triple-negative breast cancer (TNBC), characterized by the absence or low expression of
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

Homologous recombination (HR) is a highly accurate DNA repair mechanism. Several HR
genes are established cancer susceptibility genes with clinically actionable pathogenic …

Background Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors (PARPi) are
targeted therapies approved for homologous recombination repair (HRR)-deficient breast …

Breast and ovarian cancers are some of the most common tumors in females, and the
genetic predisposition is emerging as one of the key risk factors in the development of these …

Homologous recombination (HR) is a highly conserved DNA repair mechanism that protects
cells from exogenous and endogenous DNA damage. Breast cancer 1 (BRCA1) and breast …

Breast cancer is the second most frequent cancer in the world. It is a heterogeneous disease
and the leading cause of cancer mortality in women. Advances in molecular technologies …

Tumours with mutations in the BRCA1/BRCA2 genes have impaired double-stranded DNA
break repair, compromised replication fork protection and increased sensitivity to replication …

Purpose PALB2 germline pathogenic variants are associated with increased breast cancer
risk and smaller increased risk of pancreatic and likely ovarian cancer. Resources for health …

Heterozygous carriers of germ-line loss-of-function variants in the DNA repair gene PALB2
are at a highly increased lifetime risk for developing breast cancer. While truncating variants …

Background With the introduction of DNA-damaging therapies into standard of care cancer
treatment, there is a growing need for predictive diagnostics assessing homologous …